Working… Menu

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03850730
Recruitment Status : Not yet recruiting
First Posted : February 22, 2019
Last Update Posted : February 22, 2019
University of North Carolina
Information provided by (Responsible Party):
Cure HHT

Brief Summary:
Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding episodes.

Condition or disease Intervention/treatment Phase
Hereditary Hemorrhagic Telangiectasia Epistaxis Drug: Pazopanib Phase 1 Phase 2

Detailed Description:
Based on frequency and nose bleed duration, a non-randomized, single arm, open label study of 30 hereditary hemorrhagic telangiectasia patients will be treated with very low dose Pazopanib [25mg-similar] for between 16 and 24 weeks.. The primary endpoint is a reduction in bleeding duration of 50% or more, along with multiple secondary related endpoints, including bleed frequency, blood counts and quality of life; as compared to 6-12 weeks of baseline characteristics. If after the first 8 weeks of therapy benefit is suboptimal, dose advance to 50mg-similar daily can be considered.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: After at least a 6 week baseline, patients will be placed on very low dose Pazopanib [25mg-similar], for 8 weeks.. If the primary bleeding duration endpoint is achieved, than the patient will continue for another 8wks, or a total of 16 weeks on the same dose. Lack of any response will result in a dose advance to 50mg for another 3mths. If a moderate change has occurred, than the 25mg dose will be continued for another 4 weeks, and if primary endpoint achieved, continue for another 12 weeks... Lack of endpoint achievement, will augment dose to 50mg and extend study for 12 weeks, or a total of 24 weeks.
Masking: None (Open Label)
Masking Description: This is an open label study and thus all personnel and patients will be aware of the assignment.
Primary Purpose: Treatment
Official Title: An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : January 2024

Arm Intervention/treatment
Experimental: Pazopanib
Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline. If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
Drug: Pazopanib
Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
Other Name: Pazopanib capsule

Primary Outcome Measures :
  1. Percent change in epistaxis duration in minutes [ Time Frame: Summed minutes of bleeding at baseline 3 weeks and the last 3 weeks of dosing, over16-24 weeks of dosing ]
    A daily electronic record of each bleed, with start and end time, provides the daily epistaxis duration, compounded over each 3 weeks of study time

Secondary Outcome Measures :
  1. Percent change in average gushing frequency [ Time Frame: Last 3 weeks of drug period vs baseline 3 weeks; over 16-24 weeks of dosing ]
    Patient rated intensity of each bleed, as in 0 or 1, averaged over 3 wk periods.

  2. Percent change in average bleed frequency [ Time Frame: Last 3 weeks compared to the baseline 3 weeks; over 16-24 weeks of dosing ]
    Annotated number of bleeds per day, and summed over 3 week periods

  3. Absolute [gm/dl] change in serum hemoglobin [ Time Frame: comparing last 6 weeks to baseline 3-6 weeks; over 16-24 weeks of drug dosing ]
    Serum values drawn every 3 weeks

  4. Change in the frequency of blood transfusions [ Time Frame: Final 6 weeks of study, compared to baseline 3-6 weeks; over 16- 24 weeks of dosing ]
    Use of packed red blood cells over 6 week time periods.

  5. Change in the frequency of IV iron infusions [ Time Frame: Last 6 weeks of dosing to first 6 weeks; over 16-24 weeks of drug administration ]
    Number of interval IV iron infusions in 6 week periods

  6. Percent change in the per bleed average epistaxis severity [ Time Frame: The final 3 weeks to the baseline 3 weeks of the study; for a16-24 week duration study ]
    Epistaxis severity score [0-10] housed in the current patient reported outcome instrument will be averaged

  7. Daily monitoring for change in systolic blood pressure [mm mercury] using daily recordings [ Time Frame: Daily from baseline through up to 24 weeks till on-drug study completion. ]
    Patients rising above 140 mm mercury, or those who increase by 20 or more mm mercury will trigger protocol defined treatments.

  8. Daily monitoring for change in diastolic blood pressure [mm mercury] [ Time Frame: Daily from baseline through up to 24 weeks till on-drug study completion ]
    Patients rising above 90 mm mercury, or those who increase by 10 mm mercury or more will trigger protocol defined treatments.

  9. Number of participants with changes in alanine aminotransferase [liver function test] [ Time Frame: Baseline and throughout the 16-24 week dosing period ]
    measurement every 3 weeks to evaluate fold increase with use of drug

  10. Monitor for active and safe trough serum drug concentrations [ Time Frame: Over 16-24 week duration of study; once at steady state for each administered dose ]
    Assays to be analyzed to evaluate the exposures done to remain within safe and effective range [1ug/ ml to 10ug/ml].....

  11. Evaluate for change in composite mental quality of life scores [ Time Frame: baseline, week 12 and at study drug-dosing end; 16, 20 or 24weeks ]
    short form health survey 36 [range 1-100, higher number representing better self-reported mental health]

  12. Evaluate for change in composite physical quality of life scores [ Time Frame: baseline, week 12 and at study drug-dosing end; up to 24 weeks. ]
    short form health survey 36 [range 1-100, higher number representing better self-reported physical health]

  13. Evaluate for change in fatigue composite scores [ Time Frame: baseline and study end; up to 24 weeks ]
    Patient-report outcome measurement information system-fatigue; [0-100 scale; lower number representing less fatigue]. Queries the degree of fatigue and the implications on physical functioning. Reduction of 5 or more in the composite score represents clinically relevant reductions in fatigue.

Other Outcome Measures:
  1. Interrogate levels of Iron stores [ Time Frame: baseline and at on-drug study end; 16, 20 or 24 weeks depending on study duration ]
    Ferritin serum levels [normal range 12 ug/ ml to 150ug/ml female, 300ug/ ml male]. However, above 30ug/ ml valued as relevant for proper erythropoiesis]

  2. Characterize change in left ventricular stress [ Time Frame: baseline and on-drug study end; 16, 20 or 24 weeks depending on study duration] ]
    NTproBNP serum values represent a surrogate for left ventricular stress [<125pg/ml normal, while above 350pg/ml high and potentially consistent with heart failure]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • a definite diagnosis of hereditary hemorrhagic telangiectasia defined as having at least 3 of the following criteria:

    • Spontaneous and recurrent epistaxis.
    • Multiple telangiectasias at characteristic sites: lips, oral cavity, fingers, nose.
    • Visceral lesions: GI telangiectasia, pulmonary, hepatic, cerebral or spinal AVMs.
    • A first degree relative with hereditary hemorrhagic telangiectasia according to these criteria.
    • OR a gene sequencing diagnosis of hereditary hemorrhagic telangiectasia

      2. Epistaxis due to hereditary hemorrhagic telangiectasia at least 2x per week, for a cumulative duration of at least 25 minutes per week

      3. Epistaxis is clinically stable during the 12 weeks prior to screening in the clinical judgment of the investigator (i.e. no major changes in frequency or duration of epistaxis).

      4. Participant agrees not to undergo cautery of nasal telangiectasias or take any experimental therapies for hereditary hemorrhagic telangiectasia other than the study drug while participating in the study.

      5. Male or female [non-child bearing potential]

Exclusion Criteria:

  1. Participant has known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib that in the opinion of the investigator contradicts their participation.
  2. Currently has untreated cerebral arterio-venous malformations (AVMs), cerebral arteriovenous fistulae, or cerebral cavernous malformations (CCMs) (Note: MRI scan does not need to be repeated at screening if AVMs, arterio-venous fistulas and CCMs were absent on a scan at age ≥18 years).
  3. Currently has perfused pulmonary AVMs with feeding artery diameter >3mm.
  4. Known significant bleeding sources other than nasal or gastrointestinal.
  5. Systemic use of a vascular endothelial growth factor inhibitor in the past 3 months or previous enrollment in this study.
  6. Active and recent onset of clinically significant diarrhea.
  7. Current or recent (in the last 5 years) malignancies (except non-melanoma skin cancers)
  8. Participant has had major surgery (e.g. surgical ligation of an AVM) or trauma within 28 days or had minor surgical procedures (e.g. central venous access line removal) within 7 days prior to dosing, the latter representing a recent wound, fracture or ulcer
  9. Participant has a planned surgery during the period to include active treatment and 6 weeks of follow up.
  10. Participant has clinically significant gastrointestinal abnormalities (other than hereditary hemorrhagic telangiectasia related vascular lesions)
  11. Participant during the 6 months prior to first dose of study drug has a history of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism, untreated deep vein thrombosis (DVT), myocardial infarction, or any other thrombotic event.
  12. QTc ≥450 msec, based on averaged QTc values of triplicate ECGs obtained over a brief recording period [The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual overread. The same QT correction formula must be used for each individual participant to determine eligibility for and withdrawal from the study.]
  13. Hgb <6 g/dL.
  14. Platelets < 100x109/L.
  15. International normalized ratio (INR) >1.2x upper limit of normal and activated partial thromboplastin time (aPTT)>1.2x upper limit of normal.
  16. Alanine Transaminase >2x upper limit of normal.
  17. Bilirubin >1.5x upper limit of normal (isolated bilirubin >1.5x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  18. Participant has poorly controlled hypertension [defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg. Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry [between screen and baseline]. At Screening, blood pressure must be assessed three times and the mean SBP/DBP must be <140/90 mmHg in order for a participant to be eligible for the study.]
  19. Substantive renal disease (eGFR <30 mL/min/1.73m2calculated using the Cockcroft-Gault formula)
  20. Echo derived left ventricular ejection fraction <30%.
  21. Thyroid stimulating hormone > upper limit of normal.
  22. Urine protein to creatinine ratio >0.3.
  23. Neutrophil count <1500/mm3.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03850730

Layout table for location contacts
Contact: Nicole Schaefer 410-357-9932
Contact: Dennis L Sprecher, MD 267-879-2599

Sponsors and Collaborators
Cure HHT
University of North Carolina
Layout table for investigator information
Principal Investigator: Raj Kasthuri, MD University of North Carolina

Layout table for additonal information
Responsible Party: Cure HHT Identifier: NCT03850730     History of Changes
Other Study ID Numbers: HT3
First Posted: February 22, 2019    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: After the PI and associates produce the primary and adjunct reports, these data can be posted on data files for public access

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cure HHT:
nose bleeds
open label
Additional relevant MeSH terms:
Layout table for MeSH terms
Telangiectasia, Hereditary Hemorrhagic
Vascular Diseases
Cardiovascular Diseases
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases
Pathologic Processes
Signs and Symptoms, Respiratory
Signs and Symptoms
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities